2021
First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
Park J, Winer E, Huntington S, von Keudell G, Vemuri S, Shukla M, Kinoshita J, Falco V, Gore S, Stone R, Abdel-Wahab O, Tallman M. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood 2021, 138: 43. DOI: 10.1182/blood-2021-151074.Peer-Reviewed Original ResearchHairy cell leukemiaAdverse eventsEfficacy of vemurafenibCR rateFebrile neutropeniaInfusion reactionsMonth 4Month 2Dose reductionDay 1Grand roundsResponse rateTreatment of HCLDrug-related adverse eventsMedian absolute CD4 countUntreated hairy cell leukemiaRefractory hairy cell leukemiaAdvisory CommitteeComplete response rateDurability of remissionGrade 1 feverMRD-negativity ratesMulti-center clinical trialSubsequent infusion reactionsAbsolute CD4 count
2020
Disability and Recovery After Hospitalization for Medical Illness Among Community‐Living Older Persons: A Prospective Cohort Study
Dharmarajan K, Han L, Gahbauer EA, Leo‐Summers L, Gill TM. Disability and Recovery After Hospitalization for Medical Illness Among Community‐Living Older Persons: A Prospective Cohort Study. Journal Of The American Geriatrics Society 2020, 68: 486-495. PMID: 32083319, PMCID: PMC7735402, DOI: 10.1111/jgs.16350.Peer-Reviewed Original ResearchConceptsAcute medical illnessProspective cohort studyMedical illnessNew disabilityCohort studySelf-managing health conditionsCommunity-living older personsHealth conditionsImmediate transitional periodCommunity-living personsPost-discharge careChronic health conditionsMean recovery timeSubgroup of personsMobility activitiesIncident disabilityHospital dischargePeriod of vulnerabilityMonth 2Follow-up interviewHospitalizationDisability prevalenceOlder personsPrior monthIllness
2017
Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)
Hopkins JO, Allred J, Hurria A, Jatoi A, Lafky JM, Cohen H, Hudis C, Winer E, Mandelblatt J, Partridge A, Carey L, Muss HB. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research And Treatment 2017, 166: 793-808. PMID: 28825227, PMCID: PMC5771504, DOI: 10.1007/s10549-017-4454-7.Peer-Reviewed Original ResearchConceptsQuality of lifeArm functionBreast cancerAdjuvant chemotherapyMusculoskeletal eventsPhysician-reported adverse eventsIncidence of lymphedemaAxillary node dissectionType of chemotherapyEORTC QLQ-BR23Breast cancer treatmentImpact of treatmentDetection of lymphedemaCALGB 49907Node dissectionAdverse eventsOlder patientsQLQ-BR23Standard therapyStudy entryWomen 65Month 2Elderly womenPatientsChemotherapy
2011
Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib
Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. Clinical Cancer Research 2011, 17: 3490-3499. PMID: 21372222, DOI: 10.1158/1078-0432.ccr-10-1359.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, PharmacologicalBiomarkers, TumorBreast NeoplasmsC-Reactive ProteinCarcinomaDose-Response Relationship, DrugFeasibility StudiesFemaleHumansLapatinibMiddle AgedQuinazolinesStroke VolumeTrastuzumabTroponin IConceptsLeft ventricular ejection fractionC-reactive proteinMedian left ventricular ejection fractionTroponin IDetectable C-reactive proteinDose-dense doxorubicinAnthracycline-based chemotherapyDose-dense chemotherapyVentricular ejection fractionProspective feasibility studyCardiac troponin IDetectable cTnIWeekly paclitaxelMonth 6CTnI levelsEjection fractionMonth 3Months 0Month 2Breast cancerEarly biomarkersPatientsChemotherapyEarly detectionTrastuzumab
2009
Short and long term impacts of diabetes peer counseling on HbA1c among Latinos: Preliminary results
Perez‐Escamilla R, Vega‐López S, Damio G, Segura‐Pérez S, Fernandez M, Calle M, Samuel G, Chhabra J, D'Agostino D. Short and long term impacts of diabetes peer counseling on HbA1c among Latinos: Preliminary results. The FASEB Journal 2009, 23: 336.8-336.8. DOI: 10.1096/fasebj.23.1_supplement.336.8.Peer-Reviewed Original ResearchIntervention groupType 2 diabetesIntervention group participantsOngoing diabetesGlycemic controlMonth 2Clinical careHome visitsControl groupWeekly visitsFirst monthPeer counselingMonthsPeer counselorsGroup differencesGroup participantsDiabetesGreater improvementPractice trialsVisitsLong-term impactGroupLong termStatistical powerTerm impactDose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.
Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea G, Modi S, Seidman A, Drullinsky P, Partridge A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L, Hudis C. Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. Cancer Research 2009, 69: 2108. DOI: 10.1158/0008-5472.sabcs-2108.Peer-Reviewed Original ResearchDd ACHER2- BCLVEF declineDose reductionHER2/neu-positive breast cancerCongestive heart failure ratesNeu-positive breast cancerAsymptomatic LVEF declineCardiac event rateDose-dense doxorubicinHeart failure ratesDose delaysExcessive diarrheaWeekly paclitaxelMedian ageCardiac safetyMonth 2Breast cancerEvent ratesCancer ResDiarrheaPilot studyLVEFLapatinibBaseline
2008
Impact of diabetes peer counseling on glycosylated hemoglobin among Latinos enrolled in the DIALBEST Trial: Preliminary results
Perez‐Escamilla R, Vega‐Lopez S, Segura‐Perez S, Damio G, Fernandez M, Calle M, Samuel G, Chhabra J, D’Agostino D. Impact of diabetes peer counseling on glycosylated hemoglobin among Latinos enrolled in the DIALBEST Trial: Preliminary results. The FASEB Journal 2008, 22: 677.19-677.19. DOI: 10.1096/fasebj.22.1_supplement.677.19.Peer-Reviewed Original ResearchControl groupIntervention groupPeer counselorsType 2 diabetesIntervention group participantsOngoing diabetesBaseline BMIGlycemic controlMonth 12Plasma glucoseMonth 2Medical appointmentsPhysical activityClinical careHome visitsWeekly visitsFirst monthPeer counselingGlucose monitoringMonthsGroup participantsDiabetesSignificant correlationInterventionGreater improvement
2002
Radiation pneumonitis in mice A severe injury model for pneumocyte engraftment from bone marrow
Theise ND, Henegariu O, Grove J, Jagirdar J, Kao PN, Crawford JM, Badve S, Saxena R, Krause DS. Radiation pneumonitis in mice A severe injury model for pneumocyte engraftment from bone marrow. Experimental Hematology 2002, 30: 1333-1338. PMID: 12423687, DOI: 10.1016/s0301-472x(02)00931-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkersBone Marrow TransplantationCell DifferentiationCell LineageEpithelial CellsFemaleGraft SurvivalIn Situ Hybridization, FluorescenceLungMaleMiceModels, AnimalPulmonary AlveoliPulmonary Surfactant-Associated Protein BRadiation ChimeraRadiation PneumonitisRNA, MessengerStem Cell TransplantationStem CellsY ChromosomeConceptsBone marrow transplantType II pneumocytesBone marrow cellsFemale miceLethal irradiationAge-matched male donorsWhole bone marrow transplantsMarrow cellsDay 5 posttransplantAlveolar lining cellsFluorescence-activated cell sorterSevere injury modelType I cellsAlveolar breakdownEntire alveoliRadiation pneumonitisB messenger RNAHistologic evidenceMarrow transplantAcute injuryMonth 2Injury modelLung tissueLining cellsBone marrow
2000
Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trialsDerivation of hepatocytes from bone marrow cells in mice after radiation‐induced myeloablation
Theise N, Badve S, Saxena R, Henegariu O, Sell S, Crawford J, Krause D. Derivation of hepatocytes from bone marrow cells in mice after radiation‐induced myeloablation. Hepatology 2000, 31: 235-240. PMID: 10613752, DOI: 10.1002/hep.510310135.Peer-Reviewed Original ResearchConceptsBone marrow cellsY chromosomeMarrow cellsFemale miceMessenger RNAWhole bone marrow transplantsAge-matched male donorsDerivation of hepatocytesSkeletal muscle regenerationSevere acute injuryAcute hepatic injuryBone marrow transplantationBone marrow transplantSimultaneous FISHFluorescence-activated cell sorterMale-derived cellsOval cell proliferationDays posttransplantationMonths posttransplantationHepatic injuryMarrow transplantationMarrow transplantAcute injuryMonth 2Hepatic engraftment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply